Immunohistochemical Marker Patterns in Female Breast Cancer

Abstract

BACKGROUND: Breast cancer (BC) represents the most common cancer in women worldwide and in Bulgaria. Its great medico-social importance determines the intensive complex research devoted to BC prevention, early diagnosis and management.
 AIM: The objective of the present investigation is to reveal some essential peculiarities of four main immunohistochemical markers used in the diagnosis of molecular subtypes of female BC.
 MATERIALS AND METHODS: During the period between December 1, 2017 and November 30, 2020, we examined a total of 128 randomly selected female BC patients operated on in Marko Markov Specialized Hospital for Active Treatment of Oncological Diseases of Varna, Bulgaria. We analyze BC molecular types and four immunohistochemical markers in BC patients. The expression of estrogen (ER) and progesterone (PR) receptors is assessed in mammary gland biopsies and surgical specimens by using the indirect immunoperoxidase method with EnVision™ FLEX MiniKit, that of HER2 with HercepTest™ and that of Ki-67 proliferation index with Leica Aperio Scan Scope AT2 device. The positivity and negativity of these receptors in single molecular subtypes is evaluated.
 RESULTS: The luminal B HER2-positive and the luminal B HER2-negative subtypes are most common - in 36.72% and 35.16% of the cases, respectively. TNBC subtype is established in 11.72%) the luminal A - in 8.59% and the non-luminal HER2-positive subtype - in 7.81% of the cases. The positive expression is statistically significantly more common in ER (t=8.972; p<0.0001) and PR (t=2.828; p<0.01), while the negative expression insignificantly prevails in HER2.
 CONCLUSION: Our immunohistochemical results in female BC patients prove the role of single receptor expression for the proper and timely decision making about the necessity and benefit of additional chemotherapy in selected surgically treated cases.